Close Menu

aneuploidy

Vendors and clinicians are struggling with how to deal with the growing number of cases of secondary findings from molecular non-invasive prenatal tests.

While there are already many companies in the space, Agilent believes its relatively quick protocol and higher-throughput capacity will set it apart from competitors' products.

Natera has installed its software on DNAnexus' platform and will use the combined solutions to provide data analysis, storage, and sharing for its genetic tests.

The data demonstrate that the performance of NIPT demonstrated in earlier smaller studies has held true in the context of a dramatically expanded group of clinical samples.

The revenue projection falls short of analyst estimates of $45 million for the quarter and $161 million for the year. 

The companies reached an exclusive deal to provide Natera's Panorama NIPT in the Indian market. 

The company's goal is to transition from a one-test provider to a full-service genetic testing company in the reproductive health and potentially other markets.

The FAST-SeqS test screens embryos for chromosomal aneuploidies prior to implantation in an in vitro fertilization setting. 

Under the agreement, VCGS will develop its own non-invasive prenatal test using Illumina's sequencing technology.

The decision invalidates 13 claims of a patent that is at the center of litigation filed by Illumina alleging infringement by Ariosa Diagnostics.

Pages

Two COVID-19 vaccine developers have released their trial protocols to build public trust, the New York Times reports.

A new analysis finds the rapid COVID-19 test from DnaNudge to be highly accurate, Reuters reports.

In Science this week: global citizens' assembly on genome-editing technologies proposed, epigenetic markers predict metformin response, and more.

According to the Verge, many US states are not including positive results from rapid COVID-19 testing in their case numbers.